Amine polymers for use as bile acid sequestrants

1. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of formula 1

wherein

R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;

R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group;

each R 20 is independently C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and

at least one of R 10 or R 30 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.

2. The amine polymer of claim 1

wherein

R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;

R 30 is derived from the amine monomer and is C 2 to C 6 alkylene;

each R 20 is independently C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and

R 10 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.

3. The amine polymer of claim 1

wherein

R 10 is derived from the crosslinking monomer and is C 8 to C 16 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;

R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and

each R 20 is independently C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group.

4. The amine polymer of claim 1 , comprising repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:

wherein each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one amide functional group, and either

(i) R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and

the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X—R 1 —X, or a combination thereof, wherein each X is independently a leaving group, R 1 is C 8 to C 16 alkylene, dimethylbiphenyl, or 1,3-bis(m-haloC m alkyl)-1H-imidazol-3-ium, 4,4′-(C x alkane-1,x-diyl)bis(1-(m-haloC m alkyl)-1-methylpiperidinium), or 1-(q-haloC q alkyl)-3-(m-(3-(p-haloC p alkyl)-1H-imidazol-3-ium-1-yl)C m alkyl-1H-imidazol-3-ium, wherein m is an integer from 2 to 14, p is an integer from 2 to 14, q is an integer from 2 to 14, and x is an integer from 2 to 8; or

(ii) R 3 is C 8 to C 16 alkylene, and the crosslinking monomer is a compound having the formula X—R 1 —X, wherein each X is independently a leaving group, R 1 is C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an awl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy.

5. The amine polymer of claim 4

wherein each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoC m alkyl, 2-(protected amino)-1-oxoC m alkyl, 2-(protected amino)-3-methyl-1-oxoC m alkyl, 2-(protected amino)-4-methyl-1-oxoC m alkyl, 2-(protected amino)-1-oxo-m-arylC m alkyl, 2-(protected amino)-m-(alkylthio)-1-oxoC m alkyl, 2-(protected amino)-m-(aryl)-1-oxoC m alkyl, 2-(protected amino)-m-carboxy-1-oxoC m alkyl, 2-(protected amino)-m-guanidino-1-oxoC m alkyl, 2-(protected amino)-(m−1)-hydroxy-1-oxoC m alkyl, 2-(protected amino)-m-hydroxy-1-oxoC m alkyl, 2-(protected amino)-m-mercapto-1-oxoC m alkyl, m-(alkylamino)-m-oxoC m alkyl, m-(alkylheterocyclo)C m alkyl, m-amino-2-(protected amino)-1-oxoC m alkyl, m-amino-2-(protected amino)-1,m-dioxoC m alkyl, m-(x-aminoC x alkyl)heterocycloC m alkyl, (m−1)-amino-m-(heterocyclo)-1-oxoC m alkyl, m-(arylalkylamino)-m-oxoC m alkyl, m-(x-(alkylthio)C x alkylamino)-m-oxoC m alkyl, m-(x-aminoC x alkylamino)-m-oxoC m alkyl, m-(x-amino-x-oxoC x alkylamino)-m-oxoC m alkyl, m-(x-carboxyC x alkylamino)-m-oxoC m alkyl, m-(heterocycloalkylamino)-m-oxoC m alkyl, m-(x-hydroxyC x alkylamino)-m-oxoC m alkyl, m-((x−1)-hydroxyC x alkylamino)-m-oxoC m alkyl, m-(x-mercaptoC x alkylamino)-m-oxoC m alkyl, m-(x-trialkylammonioC x alkyl)heterocycloC m alkyl, m-(x-(2-(alkoxy)benzamido)C x alkylamino)-m-oxoC m alkyl, m-(x-(3-(alkoxy)benzamido)C x alkylamino)-m-oxoC m alkyl, m-(x-(4-(alkoxy)benzamido)C x alkylamino)-m-oxoC m alkyl, a ligand of formula 4

*—R 46 —R 47 —R 48   (4)

or a combination thereof, wherein R 46 is C 6 to C 16 alkylene, R 47 is 1,y-bis(1-methylpiperidin-4-yl)C y alkylene, R 48 is C 6 to C 16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.

6. The amine polymer of claim 1 wherein R 10 is C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy.

7. The amine polymer of claim 6 wherein R 10 is —CH 2 —CH(OH)—CH 2 —.

8. The amine polymer of claim 7 wherein R 30 is decylene.

9. The amine polymer of claim 7 wherein R 30 is dodecylene.

10. The amine polymer of claim 1 wherein the binding affinity for bile acids is at least about 0.46 mmol/g when measured using an in vitro A assay,

wherein the in vitro binding affinity for bile salts is determined under conditions that are intended to mimic in certain respects those conditions found in the lower small intestine, and wherein the amine polymer is analyzed using assay A (protocol 1) that combines the polymer to be analyzed in a desired concentration with a solution that mimics certain conditions present in the lower small intestine, after a period of time, the polymers are recovered by centrifugation and the supernatants are sampled, filtered to remove any remaining particulates and assayed for ion concentrations by liquid chromatography (LC), and wherein by comparing the equilibrium concentrations of glycocholate (GC eq ), glycodeoxycholate (GDC eq ), oleyl glycerol (OG eq ) and/or oleic acid (OA eq ) in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of each component bound under these experimental conditions in mmoles/g polymer is calculated.

11. The amine polymer of claim 1 wherein the binding capacity for bile acids is at least about 2.22 mmol/g when measured using the B assay,

wherein the in vitro binding capacity for bile salts is determined under conditions that are intended to mimic in certain respects those conditions found in the upper small intestine after a meal, the amine polymer is analyzed using Assay B (protocol 2) in that the polymer to be analyzed is combined in a desired concentration with a solution that mimics certain conditions present in the upper small intestine, after a period of time, the polymers are recovered by centrifugation and the supernatants are sampled, filtered to remove any remaining particulates and assayed for ion concentrations by liquid chromatography (LC), and wherein by comparing the equilibrium concentrations of glycocholate (GC eq ), glycodeoxycholate (GDC eq ), oleyl glycerol (OG eq ) and/or oleic acid (OA eq ) in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of each component bound under these experimental conditions in mmoles/g polymer is calculated.

12. The amine polymer of claim 1 wherein the amine polymer is derived from the polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer comprises N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-diaminododecane and the crosslinking monomer comprises 1,3-dichloropropanol.

13. A method of reducing serum LDL-cholesterol in an animal subject comprising administering an effective amount of an amine polymer of claim 1 to an animal subject in need thereof.

14. The method of claim 13 further comprising administering an agent that treats dyslipidemia to an animal subject.

15. The method of claim 14 wherein the agent that treats dyslipidemia is a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, a fibrate, a cholesterol absorption inhibitor, niacin (i.e. nicotinic acid or derivatives thereof), a phytosterol, an intestinal lipase inhibitor, an intestinal or secreted phospholipase A2 inhibitor, inhibitors of the synthesis or normal activity of Apo-B100, agonists of the synthesis or normal activity of ApoA, or any agent that modulates cholesterol absorption or metabolism, or a combination thereof to the animal subject.

16. The method of claim 15 wherein the agent that treats dyslipidemia is a HMG CoA reductase inhibitor, the HMG CoA reductase inhibitor comprising a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and a combination thereof.

17. The method of claim 15 wherein the agent that treats dyslipidemia is a fibrate, the fibrate comprising benzafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, or a combination thereof.